Pharmacological evidence for beta3 adrenoceptors in the control of rat gastric acid secretion.
The effect of the beta3-adrenoceptor agonist BRL37344 on gastric acid secretion evoked by different secretory stimuli was investigated in anaesthetized rats with lumen-perfused stomachs in comparison with the beta2-adrenoceptor agonist clenbuterol. Intravenous injections of BRL37344 (1-10 micromol/kg) and clenbuterol (0.01-1 micromol/kg) dose-dependently reduced 2-deoxy-D-glucose-induced acid secretion, with BRL37344 about forty times less potent than clenbuterol. BRL37344 (0.1-3 micromol/kg) inhibited pentagastrin-induced acid output, whereas clenbuterol was effective only at high doses (10-100 micromol/kg). The inhibitory effect of BRL37344 on pentagastrin-induced acid secretion was not modified by the nonselective beta-adrenoceptor antagonist propranolol, but it was prevented by bupranolol, a beta3-adrenoceptor antagonist. Furthermore, neither BRL37344 (10 micromol/kg) nor clenbuterol (100 micromol/kg) modified the acid secretion induced by histamine. These data suggest that beta3 adrenoceptors have an inhibitory role in the control of rat gastric acid secretion induced by indirect stimuli.
Adami
Maristella
M
Department of Human Anatomy, Pharmacology and Forensic Medicine, Section of Pharmacology, University of Parma, Via Volturno 39, 43100 Parma, Italy.
Coruzzi
Gabriella
G
Sotirov
Emil
E
Bertini
Simone
S
Soldani
Giulio
G
D058673:Adrenergic beta-3 Receptor Antagonists; D000704:Analysis of Variance; D000818:Animals; D004195:Disease Models, Animal; D005744:Gastric Acid / Q000378:metabolism*; D005753:Gastric Mucosa / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D011336:Probability; D051381:Rats; D017208:Rats, Wistar; D012016:Reference Values; D012680:Sensitivity and Specificity
D058673:Adrenergic beta-3 Receptor Antagonists